Scarica l'app Stockscreener
75.78
0.86%
-0.66
Dopo l'orario di chiusura:
75.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$76.44
Aprire:
$72.93
Volume 24 ore:
9.24M
Relative Volume:
2.31
Capitalizzazione di mercato:
$29.72B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
52.62
EPS:
1.44
Flusso di cassa netto:
$570.80M
1 W Prestazione:
-0.29%
1M Prestazione:
-6.24%
6M Prestazione:
+7.19%
1 anno Prestazione:
+9.10%
Intervallo 1D:
$71.80
$75.96
Intervallo di 1 settimana:
$71.80
$78.96
Portata 52W:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
75.78 | 29.98B | 4.30B | 571.50M | 570.80M | 1.44 |
|
ABT
Abbott Laboratories
|
134.57 | 233.52B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
98.23 | 145.95B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
377.84 | 144.08B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
95.59 | 121.32B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
74.55 | 44.15B | 5.69B | 1.41B | 577.90M | 6.95 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom stock falls after Hunterbrook issues short report on G7 device - Investing.com Canada
DexCom (DXCM) Shares Decline 3% After Short Report - GuruFocus
Dexcom’s Fatal Flaws - Hunterbrook
Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA - Benzinga
DexCom falls after short report from Hunterbrook - Seeking Alpha
DexCom, Inc. (NASDAQ:DXCM) Receives $99.89 Average Price Target from Analysts - MarketBeat
DexCom, Inc. (DXCM): A Bull Case Theory - Yahoo Finance
DexCom Experiences Shift in Technical Trend Amid Strong Financial Performance - Markets Mojo
Does DexCom's Interim Leadership Shift Alter the Strategic Outlook for DXCM? - uk.finance.yahoo.com
BlackRock Fund Dividend Reset Offers 9.2% Yield at a Discount - Investing.com
Will DexCom Inc outperform tech stocksJuly 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - خودرو بانک
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025 - Business Wire
Local Tennis Star Named To National Dexcom U Roster For Athletes With Diabetes - Osprey Observer
Wall Street is Bullish on DexCom (DXCM), Here’s Why - MSN
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Insulet names new CFO; Dexcom CEO on leave - MedTech Dive
DexCom, Inc. Announces CEO Changes, Effective September 14, 2025 - MarketScreener
Dexcom IncCEO Kevin R. Sayer takes temporary medical leaveSEC filing - MarketScreener
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change - MSN
DexCom (DXCM) Appoints Interim CEO Amid Executive Medical Leave - GuruFocus
DexCom stock in focus as CEO takes medical leave (DXCM:NASDAQ) - Seeking Alpha
UBM Development : Dexcom leases 2,000 square meters at Timber Peak – first leasing success for Mainz’s first timber-hybrid high-rise - MarketScreener
Bearish Setup: Is DexCom Inc stock undervalued right nowMarket Performance Report & Low Drawdown Momentum Ideas - خودرو بانک
U.S. FDADexcom issues correction for G7 apps & One+ apps - MarketScreener
Market Outlook: Is DexCom Inc a strong growth stockRate Hike & High Win Rate Trade Alerts - خودرو بانک
DexCom (DXCM) Stock Is Up, What You Need To Know - TradingView
Pullback Watch: Is US Bancorp Preferred Security subject to activist investor interest2025 Sector Review & Free Reliable Trade Execution Plans - خودرو بانک
Dexcom spotlights upcoming feature launches, improved health outcomes at EASD 2025 - Drug Store News
Dexcom, Inc. Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness with Dexcom Glucose Biosensing At EASD 2025 - MarketScreener
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside - The Globe and Mail
Acadian Asset Management LLC Has $12.87 Million Stake in DexCom, Inc. $DXCM - MarketBeat
30,516 Shares in DexCom, Inc. $DXCM Bought by Fred Alger Management LLC - MarketBeat
MBB Public Markets I LLC Takes Position in DexCom, Inc. $DXCM - MarketBeat
Insider Selling: DexCom (NASDAQ:DXCM) Director Sells 667 Shares of Stock - MarketBeat
Voleon Capital Management LP Buys 19,188 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom (NASDAQ:DXCM) Stock Rating Lowered by Oppenheimer - MarketBeat
Adage Capital Partners GP L.L.C. Sells 540,000 Shares of DexCom, Inc. $DXCM - MarketBeat
Alliancebernstein L.P. Decreases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom (NASDAQ:DXCM) EVP Sadie Stern Sells 1,466 Shares - MarketBeat
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.25%
3.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):